These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 20392347

  • 1. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment.
    Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D.
    Int J Tuberc Lung Dis; 2010 May; 14(5):551-9. PubMed ID: 20392347
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial.
    Chan PC, Yang CH, Chang LY, Wang KF, Lu BY, Lu CY, Shao PL, Hsueh PR, Fang CT, Huang LM.
    Int J Tuberc Lung Dis; 2012 May; 16(5):633-8. PubMed ID: 22410137
    [Abstract] [Full Text] [Related]

  • 5. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.
    Jiménez-Fuentes MA, de Souza-Galvao ML, Mila Augé C, Solsona Peiró J, Altet-Gómez MN.
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):326-32. PubMed ID: 23407221
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection.
    Menzies D, Dion MJ, Francis D, Parisien I, Rocher I, Mannix S, Schwartzman K.
    Int J Tuberc Lung Dis; 2005 Dec; 9(12):1343-8. PubMed ID: 16466056
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain.
    Anibarro L, Casas S, Paz-Esquete J, Gonzalez L, Pena A, Guerra MR, Sande D, Calviño L, Santin M, Mycobacteria Study Group (GEIM) of Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC).
    Int J Tuberc Lung Dis; 2010 Jun; 14(6):701-7. PubMed ID: 20487607
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
    Fluegge KR.
    J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
    [Abstract] [Full Text] [Related]

  • 13. Changes in QuantiFERON®-TB Gold In-Tube results during treatment for tuberculous infection.
    Bastos ML, Menzies D, Belo MT, Teixeira EG, de Abreu ST, Antas PR, Trajman A.
    Int J Tuberc Lung Dis; 2013 Jul; 17(7):909-16. PubMed ID: 23743310
    [Abstract] [Full Text] [Related]

  • 14. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.
    Ziakas PD, Mylonakis E.
    Clin Infect Dis; 2009 Dec 15; 49(12):1883-9. PubMed ID: 19911936
    [Abstract] [Full Text] [Related]

  • 15. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
    Campbell JR, Trajman A, Cook VJ, Johnston JC, Adjobimey M, Ruslami R, Eisenbeis L, Fregonese F, Valiquette C, Benedetti A, Menzies D.
    Lancet Infect Dis; 2020 Mar 15; 20(3):318-329. PubMed ID: 31866327
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children.
    Bright-Thomas R, Nandwani S, Smith J, Morris JA, Ormerod LP.
    Arch Dis Child; 2010 Aug 15; 95(8):600-2. PubMed ID: 20530147
    [Abstract] [Full Text] [Related]

  • 17. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF, Wang L, Liu GJ, Wen J, Sun X, Xie Y, Li YP.
    Int J Tuberc Lung Dis; 2006 Oct 15; 10(10):1080-90. PubMed ID: 17044199
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.
    Ena J, Valls V.
    Clin Infect Dis; 2005 Mar 01; 40(5):670-6. PubMed ID: 15714411
    [Abstract] [Full Text] [Related]

  • 20. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.
    White MC, Tulsky JP, Lee JR, Chen L, Goldenson J, Spetz J, Kawamura LM.
    J Correct Health Care; 2012 Apr 01; 18(2):131-42. PubMed ID: 22419641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.